CONMED Q3 sales fell 0.7% to $335.6 million; adjusted EPS down 3.2% to $1.04
CONMED reported third quarter 2026 net sales of $335.6 million, down 0.7% from a year earlier, and adjusted diluted EPS of $1.04, down 3.2%. GAAP diluted EPS was $0.66, up from $0.09, and the company updated its full year 2026 guidance to net sales of $1,360 million to $1,366 million and adjusted diluted EPS of $4.54 to $4.61. The picture is mixed for shareholders: the adjusted EPS range moved higher, while the top end of the sales range was lowered.
Key points
- Third quarter net sales were $335.6 million, down 0.7%; excluding GI product offering exits, organic constant currency net sales grew 6.7%.
- Domestic sales fell 11.0% as reported, while international sales rose 13.1% as reported.
- Full year 2026 net sales guidance is $1,360 million to $1,366 million, versus prior guidance of $1,358 million to $1,373 million.
- Full year 2026 adjusted diluted EPS guidance is $4.54 to $4.61, versus prior guidance of $4.48 to $4.60.
The filing
Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.